Portfolio company RoosterBio Announce Collaboration with Waisman Biomanufacturing For GMP Manufacturing of Cell & Exosome Therapies

Portfolio company RoosterBio today announced a collaboration with Waisman Biomanufacturing to deliver an end-to-end solution for the development and manufacturing of cell and exosome-based therapeutics, including the critical raw materials, expert process development in both 2D and 3D systems, advanced analytical characterization, regulatory support packages, and proven cGMP manufacturing capabilities. Advanced therapy developers in both industry and academia can now accelerate and de-risk their progression into clinical trials by leveraging this new strategic collaboration.